The only safe haven since Jan 2022, with strong dividend. No blowout earning report in April (slight disappointment in some areas) yet still not getting beaten.
What are the long term prospects with abbvie? Should I buy more?
The only safe haven since Jan 2022, with strong dividend. No blowout earning report in April (slight disappointment in some areas) yet still not getting beaten.
What are the long term prospects with abbvie? Should I buy more?
Leave a Reply